LeadIQ logo
Learn more at LeadIQ.com

Insights

Growing Funding Apmonia Therapeutics has attracted recent venture funding exceeding 11 million USD and additional non-dilutive capital, indicating strong investor confidence and expanding financial capacity to support drug development and partnership opportunities.

European Expansion The company's establishment of a dedicated R&D subsidiary in Belgium and recent strategic hires demonstrate a focus on expanding its research capabilities within Europe, offering potential for regional collaborations and partnerships.

Innovative Portfolio With a pipeline of drug candidates and a proprietary in silico discovery platform targeting cancer, Apmonia presents opportunities for licensing, co-development, or supply of novel therapeutic peptides and diagnostic tools.

Recognized Innovation Winning significant funding at the i-Nov Innovation Contest and securing licensing agreements with SATT Nord highlight the company's innovative edge and potential for partnerships focused on cutting-edge biomedical technologies.

Early-Stage Market Position Operating with modest revenue but substantial research funding and a focused niche in personalized immunotherapy, Apmonia offers opportunities to align with large biotech and pharma players seeking innovative cancer treatments.

Apmonia Therapeutics Tech Stack

Apmonia Therapeutics uses 8 technology products and services including oEmbed, Shopify, JSON-LD, and more. Explore Apmonia Therapeutics's tech stack below.

  • oEmbed
    Dev Tools
  • Shopify
    E-commerce
  • JSON-LD
    Javascript Frameworks
  • jQuery Migrate
    Javascript Libraries
  • Swiper
    Javascript Libraries
  • Yoast SEO
    Search Engines
  • Essential Addons for Elementor
    Web Platform Extensions
  • jQuery.scrollTo
    Web Tools And Plugins

Media & News

Apmonia Therapeutics's Email Address Formats

Apmonia Therapeutics uses at least 1 format(s):
Apmonia Therapeutics Email FormatsExamplePercentage
F.Last@apmonia-therapeutics.comJ.Doe@apmonia-therapeutics.com
88%
L.First@apmonia-therapeutics.comD.John@apmonia-therapeutics.com
12%

Frequently Asked Questions

Where is Apmonia Therapeutics's headquarters located?

Minus sign iconPlus sign iconApmonia Therapeutics's main headquarters is located at 2 Esplanade Roland Garros Reims, Grand Est 51100 France. The company has employees across 1 continents, including Europe.

What is Apmonia Therapeutics's official website and social media links?

Minus sign iconPlus sign iconApmonia Therapeutics's official website is apmonia-therapeutics.com and has social profiles on LinkedInCrunchbase.

What is Apmonia Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign iconApmonia Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Apmonia Therapeutics have currently?

Minus sign iconPlus sign iconAs of June 2026, Apmonia Therapeutics has approximately 19 employees across 1 continents, including Europe. Key team members include Chief Executive Officer: A. J.Chief Regulatory Officer: L. L.Chief Operating Officer: S. G.. Explore Apmonia Therapeutics's employee directory with LeadIQ.

What industry does Apmonia Therapeutics belong to?

Minus sign iconPlus sign iconApmonia Therapeutics operates in the Biotechnology Research industry.

What technology does Apmonia Therapeutics use?

Minus sign iconPlus sign iconApmonia Therapeutics's tech stack includes oEmbedShopifyJSON-LDjQuery MigrateSwiperYoast SEOEssential Addons for ElementorjQuery.scrollTo.

What is Apmonia Therapeutics's email format?

Minus sign iconPlus sign iconApmonia Therapeutics's email format typically follows the pattern of F.Last@apmonia-therapeutics.com. Find more Apmonia Therapeutics email formats with LeadIQ.

How much funding has Apmonia Therapeutics raised to date?

Minus sign iconPlus sign icon As of June 2026, Apmonia Therapeutics has raised $7.6M in funding. The last funding round occurred on Jul 15, 2024 for $7.6M.

When was Apmonia Therapeutics founded?

Minus sign iconPlus sign iconApmonia Therapeutics was founded in 2019.

Apmonia Therapeutics

Biotechnology ResearchGrand Est, France11-50 Employees

Apmonia Therapeutics is a clinical-stage biotechnology company developing innovative peptide therapeutics designed to target the tumor microenvironment and improve outcomes for patients with solid tumors.

Our approach focuses on overcoming one of oncology’s greatest challenges: the tumor microenvironment, a protective ecosystem that drives tumor growth, immune escape, and treatment resistance.

Our lead candidate, TAX2, is a first-in-class peptide modulator of the TSP-1/CD47 pathway. Following strong preclinical results and CTA approval in Europe, TAX2 is entering Phase 1/2a clinical development in advanced solid tumors.

Section iconCompany Overview

Headquarters
2 Esplanade Roland Garros Reims, Grand Est 51100 France
Website
apmonia-therapeutics.com
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2019
Employees
11-50

Section iconMedia & News

Section iconFunding & Financials

  • $7.6M

    Apmonia Therapeutics has raised a total of $7.6M of funding over 4 rounds. Their latest funding round was raised on Jul 15, 2024 in the amount of $7.6M.

  • $1M

    Apmonia Therapeutics's revenue is estimated to be in the range of $1M

Section iconFunding & Financials

  • $7.6M

    Apmonia Therapeutics has raised a total of $7.6M of funding over 4 rounds. Their latest funding round was raised on Jul 15, 2024 in the amount of $7.6M.

  • $1M

    Apmonia Therapeutics's revenue is estimated to be in the range of $1M

Company Leadership

  • Stylized image of a person
    A. J.
    Chief Executive Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    L. L.
    Chief Regulatory Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. G.
    Chief Operating Officer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. L.
    Co-Founder And Board Member
    Phone icon
    Mobile Phone
  • Stylized image of a person
    S. D.
    Co-Founder & Chair Of The Scientific And Clinical Advisory Board
    Phone icon
    Mobile Phone

Employee Directory

  • Stylized image of a person
    A. P.
    Responsable Projets Drug Discovery / Project Manager - Drug Discovery
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. M.
    Senior Non-Clinical Project Manager
    Phone icon
    Mobile Phone
  • Stylized image of a person
    J. R.
    Founders Representative - Board Member
    Phone icon
    Mobile Phone
  • Stylized image of a person
    M. G.
    Computational Engineer
    Phone icon
    Mobile Phone
  • Stylized image of a person
    A. F.
    Directeur Financiers À Temps Partagé
    Phone icon
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.